About Predicine
Predicine Inc. is a precision medicine company specializing in next-generation liquid biopsy technology for cancer diagnostics and monitoring. The company's proprietary GeneRADAR platform enables simultaneous profiling of cell-free DNA and RNA from blood and urine samples, providing comprehensive molecular insights into cancer biology. Predicine offers a portfolio of CLIA-certified and CAP-accredited genomic profiling assays including PredicineATLAS (600-gene panel), PredicineCARE (200-gene cfDNA assay), PredicineRNA (88-gene fusion/splicing detection), PredicineHEME (259-gene hematologic malignancies panel), and PredicineBEACON (MRD detection). The company operates CLIA/CAP-certified laboratories in California and Shanghai, supporting biomarker-driven clinical trials for leading biopharmaceutical companies across the United States and China. Predicine's technology enables treatment selection, disease monitoring, minimal residual disease detection, and assessment of key biomarkers including TMB, MSI, HRD, and homologous recombination deficiency. The company pioneered urine-based liquid biopsy for genitourinary cancers, offering a truly non-invasive alternative to blood-based testing. Predicine serves biopharmaceutical partners conducting Phase I-III clinical trials, providing end-to-end biomarker solutions from target discovery through commercial launch.
Clinical Focus
Medical conditions and clinical areas addressed by Predicine.
Who It Serves
Milestones & Awards
Recent Milestones
Published research on ctDNA biomarkers in giredestrant response for breast cancer, RAS-targeted therapy combinations, and tumor-informed ctDNA in HPV-independent head and neck cancer
Key Partnerships
Company Details
- Headquarters
- Hayward, CA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.